Clinical Trials Logo

Filter by:
  • Enrolling by invitation  
  • Page [1]
NCT ID: NCT04394455 Enrolling by invitation - Anxiety Clinical Trials

Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms

Start date: June 30, 2020
Phase: N/A
Study type: Interventional

The purpose of this randomized controlled trial is to determine the effect of two behavioral interventions: brief cognitive-behavioral therapy and crisis intervention therapy through telepsychiatry, over the level of perceived stress, anxiety, depression and post-traumatic stress symptoms during the COVID-19 pandemic in medical residents and medical staff at three hospitals in two cities of Honduras.

NCT ID: NCT02946658 Enrolling by invitation - Lung Disease Clinical Trials

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

ADcSVF-COPD
Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized by long-term, often progressive state of poor airflow. Primary symptoms include low oxygen tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and interference with oxygen-carbon dioxide exchange. Air pollution and tobacco smoking are felt to be the most common cause of these issues. Diagnostic testing is based on poor airflow measured by lung function studies and whose symptoms do not improve much with antiasthma bronchodilators. Study is an interventional study to document the safety and efficacy of use of AD-cSVF in chronic broncho-pulmonary disease groups.

NCT ID: NCT02570737 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

Latin American Pulmonary Hypertension Registry

RELAHP
Start date: April 2014
Phase: N/A
Study type: Observational [Patient Registry]

The RELAHP registry is a Latin-American multinational, multicenter, prospective observational registry-type cohort study, which pretends to identify clinical characteristics, clinical course, management and outcome of all forms of pulmonary hypertension (PH). All consecutively consented patients newly diagnosed with WHO Group I-V PH according to specific hemodynamic criteria on right heart catheterization at the participating centers will be enrolled. Patients will be followed six-monthly for a minimum of five years from the time of enrollment.